Posted by Michael Wonder on 02 Mar 2017
NICE expands positive recommendation for Erbitux as first-line treatment for RAS wild type mCRC
2 March 2017 - NICE’s recommendation is a significant step forward in Merck’s aspiration to ensure cancer patients have optimal access to effective treatments worldwide.
Merck announced today that the UK NICE has issued a positive Final Appraisal Determination recommending the routine National Health Service use of Erbitux (cetuximab) in combination with either FOLFIRI or FOLFOX as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer.
Erbitux has long been established and reimbursed as a first-line standard-of-care treatment option in most European countries and many other countries worldwide.
